VTGN (Vistagen Therapeutics) Preferred Stock: $0.00 Mil (As of Mar. 2026)


VTGN Vistagen Therapeutics Inc VTGN
29 GF Score
Price $0.26
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Preferred Stock?

Vistagen Therapeutics VTGN +3.41% 29 Preferred Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 29/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review.

Preferred stock is a special equity security that has properties of both equity and debt. Vistagen Therapeutics's preferred stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Vistagen Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-22.42 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Vistagen Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.90.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Vistagen Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.38.


Vistagen Therapeutics  (NAS:VTGN) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Vistagen Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Vistagen Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Vistagen Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vistagen Therapeutics Preferred Stock Related Terms


Vistagen Therapeutics Preferred Stock Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Preferred Stock Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VTGN
29GF Score
Vistagen Therapeutics Inc VTGN
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of $0.00 Mil mean?
Vistagen Therapeutics (VTGN) has a Preferred Stock of $0.00 Mil as of Mar. 2026. Preferred Stock represents the par value of a company's preferred shares. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Preferred Stock too high?
Vistagen Therapeutics' current Preferred Stock is $0.00 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Preferred Stock compare to PSTV and KYNB?
Vistagen Therapeutics' Preferred Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Preferred Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.26 — trading 88.3% below its estimated fair value. The current Preferred Stock is $0.00 Mil. Vistagen Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Preferred Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.26 is trading 88.3% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Preferred Stock: $0.00 Mil
  • GF Value™: $2.20 vs. price of $0.26 (88.3% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score

Get the complete analysis for VTGN

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$2.20
GF Value